Trial Profile

A Study of Safety and Immunogenicity of 10-valent and 13-valent Pneumococcal Conjugate Vaccines to Inform Policy Regarding Pneumococcal Vaccination of Papua New Guinean Children

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 25 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pneumococcal 10-valent vaccine conjugate (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate (Primary) ; Pneumococcal vaccine
Indications Pneumococcal infections
Focus Pharmacodynamics
Acronyms 10v13vPCV Trial; PCV1103

19 Jul 2023 Results assessing pneumococcal carriage rates, serotype distribution, and antimicrobial susceptibility in PNG children after vaccination, published in the Vaccine
09 Aug 2021 Results (n=219) comparing vaccine and non-vaccine serotype carriage density in PCV13-vaccinated and unvaccinated Papua New Guinean infants from this and pneumonia and meningitis aetiology study published in the Vaccine
20 May 2021 Results (n=101) published in the Vaccine

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com